Which has better valuation & earnings, HNGE or PGNY?

Progyny has higher revenue and earnings than Hinge Health. Progyny is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hinge Health $720.06M 10.96 -$528.26M $1.28 76.44 Progyny $1.31B 1.49 $58.52M $0.92 27.62

Is HNGE or PGNY more profitable?

Hinge Health has a net margin of 15.15% compared to Progyny's net margin of 6.00%. Hinge Health's return on equity of 51.60% beat Progyny's return on equity. Company Net Margins Return on Equity Return on Assets Hinge Health 15.15% 51.60% 14.16% Progyny 6.00% 15.98% 10.65%

Does the media favor HNGE or PGNY?

In the previous week, Hinge Health had 7 more articles in the media than Progyny. MarketBeat recorded 14 mentions for Hinge Health and 7 mentions for Progyny. Progyny's average media sentiment score of 1.00 beat Hinge Health's score of 0.48 indicating that Progyny is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hinge Health 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Progyny 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, PGNY or CHE?

Chemed has higher revenue and earnings than Progyny. Chemed is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.31B 1.49 $58.52M $0.92 27.62 Chemed $2.60B 2.56 $265.24M $19.91 25.57

Is PGNY or CHE more profitable?

Chemed has a net margin of 10.60% compared to Progyny's net margin of 6.00%. Chemed's return on equity of 31.77% beat Progyny's return on equity. Company Net Margins Return on Equity Return on Assets Progyny 6.00% 15.98% 10.65% Chemed 10.60% 31.77% 18.90%

Does the media refer more to PGNY or CHE?

In the previous week, Progyny had 2 more articles in the media than Chemed. MarketBeat recorded 7 mentions for Progyny and 5 mentions for Chemed. Progyny's average media sentiment score of 1.00 beat Chemed's score of 0.26 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, PGNY or HIMS?

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.31B 1.49 $58.52M $0.92 27.62 Hims & Hers Health $2.58B 2.77 $128.37M -$0.63 N/A

Does the media refer more to PGNY or HIMS?

In the previous week, Hims & Hers Health had 39 more articles in the media than Progyny. MarketBeat recorded 46 mentions for Hims & Hers Health and 7 mentions for Progyny. Progyny's average media sentiment score of 1.00 beat Hims & Hers Health's score of 0.07 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 3 Very Positive mention(s) 6 Positive mention(s) 35 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, RDNT or PGNY?

Progyny has lower revenue, but higher earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RadNet $2.27B 2.43 -$18.65M -$0.27 N/A Progyny $1.31B 1.49 $58.52M $0.92 27.62

Is RDNT or PGNY more profitable?

Progyny has a net margin of 6.00% compared to RadNet's net margin of -0.93%. Progyny's return on equity of 15.98% beat RadNet's return on equity. Company Net Margins Return on Equity Return on Assets RadNet -0.93% 2.61% 0.91% Progyny 6.00% 15.98% 10.65%

Does the media prefer RDNT or PGNY?

In the previous week, Progyny had 4 more articles in the media than RadNet. MarketBeat recorded 7 mentions for Progyny and 3 mentions for RadNet. RadNet's average media sentiment score of 1.17 beat Progyny's score of 1.00 indicating that RadNet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Progyny 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, BLLN or PGNY?

Progyny has higher revenue and earnings than Billiontoone. Progyny is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Billiontoone $305.11M 17.00 $7.45M $0.70 157.02 Progyny $1.31B 1.49 $58.52M $0.92 27.62

Is BLLN or PGNY more profitable?

Billiontoone has a net margin of 8.04% compared to Progyny's net margin of 6.00%. Progyny's return on equity of 15.98% beat Billiontoone's return on equity. Company Net Margins Return on Equity Return on Assets Billiontoone 8.04% 9.96% 5.35% Progyny 6.00% 15.98% 10.65%

Does the media refer more to BLLN or PGNY?

In the previous week, Billiontoone had 8 more articles in the media than Progyny. MarketBeat recorded 15 mentions for Billiontoone and 7 mentions for Progyny. Progyny's average media sentiment score of 1.00 beat Billiontoone's score of 0.37 indicating that Progyny is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Billiontoone 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Progyny 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Progyny (PGNY) Competitors

$25.41 +0.62 (+2.50%)

As of 01:04 PM Eastern

Compare

PGNY vs. HNGE, CHE, HIMS, RDNT, and BLLN

Should you buy Progyny stock or one of its competitors? Progyny's main competitors and comparable companies include Hinge Health (HNGE), Chemed (CHE), Hims & Hers Health (HIMS), RadNet (RDNT), and Billiontoone (BLLN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Progyny compare to Hinge Health?

Hinge Health (NYSE:HNGE) and Progyny (NASDAQ:PGNY) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Progyny has higher revenue and earnings than Hinge Health. Progyny is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hinge Health	$720.06M	10.96	-$528.26M	$1.28	76.44
Progyny	$1.31B	1.49	$58.52M	$0.92	27.62

In the previous week, Hinge Health had 7 more articles in the media than Progyny. MarketBeat recorded 14 mentions for Hinge Health and 7 mentions for Progyny. Progyny's average media sentiment score of 1.00 beat Hinge Health's score of 0.48 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hinge Health	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Progyny	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hinge Health has a net margin of 15.15% compared to Progyny's net margin of 6.00%. Hinge Health's return on equity of 51.60% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hinge Health	15.15%	51.60%	14.16%
Progyny	6.00%	15.98%	10.65%

94.9% of Progyny shares are held by institutional investors. 18.9% of Hinge Health shares are held by company insiders. Comparatively, 9.9% of Progyny shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Hinge Health has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Progyny has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

Hinge Health presently has a consensus target price of $105.33, suggesting a potential upside of 7.66%. Progyny has a consensus target price of $34.36, suggesting a potential upside of 35.24%. Given Progyny's higher possible upside, analysts clearly believe Progyny is more favorable than Hinge Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hinge Health	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Summary

Hinge Health beats Progyny on 11 of the 16 factors compared between the two stocks.

How does Progyny compare to Chemed?

Progyny (NASDAQ:PGNY) and Chemed (NYSE:CHE) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

94.9% of Progyny shares are held by institutional investors. Comparatively, 95.8% of Chemed shares are held by institutional investors. 9.9% of Progyny shares are held by insiders. Comparatively, 3.3% of Chemed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Progyny presently has a consensus target price of $34.36, suggesting a potential upside of 35.24%. Chemed has a consensus target price of $554.60, suggesting a potential upside of 8.93%. Given Progyny's stronger consensus rating and higher probable upside, equities research analysts clearly believe Progyny is more favorable than Chemed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Chemed	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Chemed has higher revenue and earnings than Progyny. Chemed is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.31B	1.49	$58.52M	$0.92	27.62
Chemed	$2.60B	2.56	$265.24M	$19.91	25.57

In the previous week, Progyny had 2 more articles in the media than Chemed. MarketBeat recorded 7 mentions for Progyny and 5 mentions for Chemed. Progyny's average media sentiment score of 1.00 beat Chemed's score of 0.26 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Chemed has a net margin of 10.60% compared to Progyny's net margin of 6.00%. Chemed's return on equity of 31.77% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
Chemed	10.60%	31.77%	18.90%

Progyny has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Chemed has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Summary

Progyny beats Chemed on 9 of the 17 factors compared between the two stocks.

How does Progyny compare to Hims & Hers Health?

Progyny (NASDAQ:PGNY) and Hims & Hers Health (NYSE:HIMS) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

94.9% of Progyny shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 9.9% of Progyny shares are owned by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.31B	1.49	$58.52M	$0.92	27.62
Hims & Hers Health	$2.58B	2.77	$128.37M	-$0.63	N/A

Progyny currently has a consensus price target of $34.36, indicating a potential upside of 35.24%. Hims & Hers Health has a consensus price target of $32.43, indicating a potential upside of 5.96%. Given Progyny's stronger consensus rating and higher probable upside, research analysts clearly believe Progyny is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Hims & Hers Health	1 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

In the previous week, Hims & Hers Health had 39 more articles in the media than Progyny. MarketBeat recorded 46 mentions for Hims & Hers Health and 7 mentions for Progyny. Progyny's average media sentiment score of 1.00 beat Hims & Hers Health's score of 0.07 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	3 Very Positive mention(s)	6 Positive mention(s)	35 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Progyny has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.42, indicating that its stock price is 142% more volatile than the broader market.

Progyny has a net margin of 6.00% compared to Hims & Hers Health's net margin of -5.51%. Progyny's return on equity of 15.98% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	6.00%	15.98%	10.65%
Hims & Hers Health	-5.51%	-6.51%	-1.20%

Summary

Progyny beats Hims & Hers Health on 11 of the 17 factors compared between the two stocks.

How does Progyny compare to RadNet?

RadNet (NASDAQ:RDNT) and Progyny (NASDAQ:PGNY) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

RadNet presently has a consensus price target of $90.00, suggesting a potential upside of 28.72%. Progyny has a consensus price target of $34.36, suggesting a potential upside of 35.24%. Given Progyny's higher probable upside, analysts clearly believe Progyny is more favorable than RadNet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Progyny has lower revenue, but higher earnings than RadNet. RadNet is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$2.27B	2.43	-$18.65M	-$0.27	N/A
Progyny	$1.31B	1.49	$58.52M	$0.92	27.62

In the previous week, Progyny had 4 more articles in the media than RadNet. MarketBeat recorded 7 mentions for Progyny and 3 mentions for RadNet. RadNet's average media sentiment score of 1.17 beat Progyny's score of 1.00 indicating that RadNet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RadNet	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Progyny	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.9% of RadNet shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 5.1% of RadNet shares are held by insiders. Comparatively, 9.9% of Progyny shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Progyny has a net margin of 6.00% compared to RadNet's net margin of -0.93%. Progyny's return on equity of 15.98% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RadNet	-0.93%	2.61%	0.91%
Progyny	6.00%	15.98%	10.65%

RadNet has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, Progyny has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

Summary

Progyny beats RadNet on 11 of the 17 factors compared between the two stocks.

How does Progyny compare to Billiontoone?

Billiontoone (NASDAQ:BLLN) and Progyny (NASDAQ:PGNY) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Billiontoone currently has a consensus price target of $125.88, indicating a potential upside of 14.52%. Progyny has a consensus price target of $34.36, indicating a potential upside of 35.24%. Given Progyny's stronger consensus rating and higher possible upside, analysts clearly believe Progyny is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Billiontoone	2 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.45
Progyny	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

94.9% of Progyny shares are held by institutional investors. 50.2% of Billiontoone shares are held by insiders. Comparatively, 9.9% of Progyny shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Billiontoone had 8 more articles in the media than Progyny. MarketBeat recorded 15 mentions for Billiontoone and 7 mentions for Progyny. Progyny's average media sentiment score of 1.00 beat Billiontoone's score of 0.37 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Billiontoone	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Progyny	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny has higher revenue and earnings than Billiontoone. Progyny is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Billiontoone	$305.11M	17.00	$7.45M	$0.70	157.02
Progyny	$1.31B	1.49	$58.52M	$0.92	27.62

Billiontoone has a net margin of 8.04% compared to Progyny's net margin of 6.00%. Progyny's return on equity of 15.98% beat Billiontoone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Billiontoone	8.04%	9.96%	5.35%
Progyny	6.00%	15.98%	10.65%

Summary

Progyny beats Billiontoone on 11 of the 16 factors compared between the two stocks.

Get Progyny News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGNY vs. The Competition

Export

Metric	Progyny	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.95B	$9.69B	$7.26B	$13.17B
Dividend Yield	N/A	2.59%	2.52%	14.19%
P/E Ratio	27.66	34.74	274.41	25.76
Price / Sales	1.49	5.53	659.61	91.46
Price / Cash	34.67	121.33	80.06	52.35
Price / Book	4.24	5.19	10.43	6.35
Net Income	$58.52M	$315.68M	$3.50B	$360.42M
7 Day Performance	-1.63%	-1.75%	-1.17%	-1.50%
1 Month Performance	-2.27%	-1.65%	-4.03%	-4.03%
1 Year Performance	18.08%	9.75%	12.93%	3.96%

Progyny Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGNY Progyny	4.3659 of 5 stars	$25.41 +2.5%	$34.36 +35.2%	+15.7%	$1.95B	$1.31B	27.66	856	Positive News Analyst Forecast Insider Trade
HNGE Hinge Health	3.5743 of 5 stars	$94.53 -0.4%	$101.93 +7.8%	+92.0%	$7.66B	$587.86M	73.85	1,437	News Coverage Analyst Forecast
CHE Chemed	3.3699 of 5 stars	$499.50 -0.9%	$530.75 +6.3%	+13.2%	$6.59B	$2.53B	25.09	15,811
HIMS Hims & Hers Health	1.7687 of 5 stars	$29.43 +5.1%	$32.43 +10.2%	-51.5%	$6.53B	$2.35B	N/A	2,442	Trending News
RDNT RadNet	3.6384 of 5 stars	$72.67 -4.4%	$90.00 +23.8%	-5.4%	$5.98B	$2.04B	N/A	11,264

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGNY) was last updated on 9/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Progyny (PGNY) Competitors

PGNY vs. HNGE, CHE, HIMS, RDNT, and BLLN

How does Progyny compare to Hinge Health?

Summary

How does Progyny compare to Chemed?

Summary

How does Progyny compare to Hims & Hers Health?

Summary

How does Progyny compare to RadNet?

Summary

How does Progyny compare to Billiontoone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Progyny (PGNY) Competitors

PGNY vs. HNGE, CHE, HIMS, RDNT, and BLLN

How does Progyny compare to Hinge Health?

Which has better valuation & earnings, HNGE or PGNY?

Does the media favor HNGE or PGNY?

Is HNGE or PGNY more profitable?

Do institutionals & insiders believe in HNGE or PGNY?

Which has more volatility and risk, HNGE or PGNY?

Do analysts rate HNGE or PGNY?

Summary

How does Progyny compare to Chemed?

Do insiders and institutionals believe in PGNY or CHE?

Do analysts rate PGNY or CHE?

Which has stronger valuation and earnings, PGNY or CHE?

Does the media refer more to PGNY or CHE?

Is PGNY or CHE more profitable?

Which has more risk and volatility, PGNY or CHE?

Summary

How does Progyny compare to Hims & Hers Health?

Do institutionals and insiders have more ownership in PGNY or HIMS?

Which has better valuation and earnings, PGNY or HIMS?

Do analysts rate PGNY or HIMS?

Does the media refer more to PGNY or HIMS?

Which has more risk & volatility, PGNY or HIMS?

Is PGNY or HIMS more profitable?

Summary

How does Progyny compare to RadNet?

Do analysts prefer RDNT or PGNY?

Which has stronger earnings & valuation, RDNT or PGNY?

Does the media prefer RDNT or PGNY?

Do insiders & institutionals hold more shares of RDNT or PGNY?

Is RDNT or PGNY more profitable?

Which has more risk & volatility, RDNT or PGNY?

Summary

How does Progyny compare to Billiontoone?

Do analysts rate BLLN or PGNY?

Do institutionals and insiders believe in BLLN or PGNY?

Does the media refer more to BLLN or PGNY?

Which has stronger earnings and valuation, BLLN or PGNY?

Is BLLN or PGNY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools